96 products were found matching "K01348"!

An inhibitor of uPA (IC50 = 0.32 µM), selective for uPA over tPA and plasmin (IC50s = 107 and 352 µM, respectively), cytotoxic to F3II mouse breast cancer cells (IC50 = 18 µM), inhibits muscle and adipose tissue invasion in an F3II murine breast cancer model at 20 mg/kg per day, decreases ethanol consumption and...

Urokinase-type plasminogen activator (uPA) is a serine protease that converts enzymatically inactive plasminogen into active plasmin. It is synthesized and released as a single polypeptide chain called pro-uPA, which contains three domains: a growth factor domain (GFD), a kringle domain, and a serine protease...

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.

Plasminogen activator, urokinase (uPA) is a secreted serine protease, cleaving the sequence Cys-Pro-Gly-Arg560-Val561-Val-Gly-Gly-Cys in plasminogen to form plasmin. Dysregulation of PLAU is often accompanied by various cancers and PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for...

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.

Plasminogen activator, urokinase (uPA) is a secreted serine protease whose Dysregulation is often accompanied by various cancers. PLAU inhibition could suppress tumor growth. Collectively, PLAU is necessary for tumor progression and can be a diagnostic and prognostic biomarker in HNSCC.

6-Aminocaproic acid is an inhibitor of the plasmin activating enzymes streptokinase, fibrinokinase, and urokinase (IC50s = ~8 µM for all in an enzyme assay). It is selective for plasmin activating enzymes over trypsin (IC50 = >500 µM). 6-Aminocaproic acid inhibits in vitro plasmin activation and fibrinolysis in a...

Gabexate is a competitive inhibitor of serine proteases that inhibits human thrombin, urokinase, plasmin, and Factor Xa (Kis = 0.97, 1.3, 1.6, and 8.5 µM, respectively)., It also inhibits bovine thrombin, Factor Xa, and trypsin, and porcine plasma kallikrein (Kis = 1.4, 2.1, 2.6, and 0.2 µM, respectively)., In...

Protein function: Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. [The UniProt Consortium]